Home › Amgen, Allergan Biosimilar Avastin Hits In Trial
 

Keywords :   


Amgen, Allergan Biosimilar Avastin Hits In Trial

2015-09-24 17:07:51| Biotech - Topix.net

Amgen and Allergan, which started their collaboration back in 2011 when Allergan was a generic drug maker called Watson Pharmaceuticals, released few details but said the drug ABP 215 had shown clinical equivalence to Avastin as measured by tumor shrinkage, duration of response and progression-free survival. Launched in 2004, Avastin is drawing $7 billion for Roche as a treatment for a variety of different cancers, about 20% to 25% of it from lung cancer.

Tags: trial hits amgen allergan

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.10Tropical Depression Fourteen Graphics
05.10Tropical Depression Fourteen Forecast Discussion Number 1
05.10Tropical Depression Fourteen Wind Speed Probabilities Number 1
05.10Tropical Depression Fourteen Public Advisory Number 1
05.10Summary for Tropical Depression Fourteen (AT4/AL142024)
05.10Tropical Depression Fourteen Forecast Advisory Number 1
05.10Hurricane Kirk Graphics
05.10Hurricane Kirk Forecast Discussion Number 25
More »